Atrial fibrillation, stroke, and acute antithrombotic therapy analysis of randomized clinical trials

Stroke

Volumn 33, Issue 11, 2002, Pages 2722-2727

  Hart, Robert G ^a   Palacio, Santiago ^a   Pearce, Lesly A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aspirin; Atrial fibrillation; Heparin; Stroke; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STROKE;

ACUTE DISEASE; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TREATMENT OUTCOME;

EID: 0036843745     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000035735.49388.4A     Document Type: Review

References (35)

1. Lamassa M, Di Carlo AA, Pracucci G, Basile AM, Trefoloni G, Vanni P, Spolveri F, Baruffi MC, Landini G, Ghetti A, Wolfe CDA, Inzitari D. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: Data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke. 2001;32: 392-398.
2. Saxena R, Lewis S, Berge E, Sandercock PAG, Koudstaal PJ, for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke. 2001;32:2333-2337.
3. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. Lancet. 1997; 349:1569-1581.
4. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997;349:1641-1649.
5. Berge E, Abdelnoor M, Nakstad PH, Sandset PM, for the HAEST Study Group (Heparin in Acute Embolic Stroke Trial). Low molecular-weight heparin vs. aspirin in patients with acute ischemic stroke and atrial fibrillation: A double blind randomised study. Lancet. 2000;355: 1205-1210.
6. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
7. Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke. JAMA. 1998:279:1265-1272.
8. Bath PMW, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson JE, O'Neill D, Orgogozo JM, Ringelstein B, van der Sande JJ, Turpie AGG, for the TAIST Investigators. Tinzaparin in acute stroke (TAIST): A randomized, aspirin-controlled trial. Lancet. 2001;358: 702-710.
9. Diener H, Ringelstein EB, von Kummer R, Langohr HD, Bewermeyer H, Landgraf H, Hennerici M, Welzel D, Grave M, Brom J, Weidinger G, for the Therapy of Patients with Acute Stroke (TOPAS) Investigators. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: Results of the TOPAS trial. Stroke. 2001:32:22-29.
10. Duke RJ, Bloch RF, Turpie AGG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke: A randomized controlled trial. Ann Intern Med. 1986;105: 825-828.
11. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998:352:1245-1251.
12. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS. Xie JX, Warlow C, Peto R, on behalf of the CAST and IST Collaborative Groups. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trials and the International Stroke Trial. Stroke. 2000:31:1240-1249.
13. Moroney JT, Bagiella E, Paik MC, Sacco RL, Desmond DW. Risk factors for early recurrence after ischemic stroke. Stroke. 1998;29:2118-2121.
14. Toni D, Argentino C, Fieschi C. Heparin versus aspirin in ischaemic stroke. Lancet. 2000;356:504-505.
15. Bath PMW, Iddenden R, Bath FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: A meta-analysis of randomized controlled trials. Stroke. 2000;31:1770-1778.
16. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: A randomized trial. Stroke. 1983;14:668-676.
17. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke. JAMA. 2000;283:1145-1150.
18. Liebeskind DS, Saver JL, Duckwiler GR, Kidwell CS, Carneado J, Starkman S, Vespa PM, Gobin P, Jahan R, Kasner SE, Vinuela F. Atrial fibrillation and intra-arterial thrombolysis. Stroke. 2001;32:370. Abstract.
19. Yoneda Y, Mori E, Uehara T, Tabuchi M. Non-valvular atrial fibrillation in acute ischaemic stroke candidates for thrombolytic therapy. Cerebrovasc Dis. 1997;7:357-358.
20. Molina C, Alvarez-Sabin J, Montaner J, Abilleira S, Arenillas J, Codina A. Timing of thrombolysis-induced recanalization acute cardioembolic stroke: A case-control study. Cerebrovasc Dis. 2001;11(suppl 4):120. Abstract.
21. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, Hommel M. Hemorrhagic transformation in acute ischemic stroke: The MAST-E Study. Stroke. 1999;30:1326-1332.
22. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke: Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997;28:957-960.
23. NINDS tPA stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
24. Tanne D, Demchuk A, Kasner SE, Grond M, Hanson S, Hamilton S, Buchan AM, Wang DZ, Wechsler LR, Zweifler R, Levine SR. A large multinational investigation to predict t-PA related symptomatic ICH in patients with acute ischemic stroke. Stroke. 1999;30:248. Abstract.
25. NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997; 28:2119-2125.
26. Tanne D, Gorman MJ, Bates VE, Kasner SE, Scott P, Verro P, Binder JR, Dayno JM, Schultz L, Levine SR, and the tPA Stroke Survey Group. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older. Stroke. 2000;31:370-375.
27. Brott TG, Kaste M, Albers GW. Analysis of the NINDS, ECASS I and ECASS II and Atlantis Data Sets. Paper presented at: 27th International Stroke Conference; February 9, 2002; San Antonio, Tex.
28. Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW, Nasco E. Cardioembolic vs. noncardioembolic stroke in atrial fibrillation: Frequency and effect of antithrombotic agents in the Stroke Prevention in Atrial Fibrillation studies. Cerebrovasc Dis. 2000;10:39-43.
29. Yonemura K, Yasaka M, Kimura K, Minematsu K, Yamaguchi T. Predisposing factors of early recurrent embolism in stroke patients with nonvalvular atrial fibrillation. Stroke. 2002;33:348. Abstract.
30. Chamorro A, Vila N, Ascaso C, Blanc R. Heparin in acute stroke with atrial fibrillation: Clinical relevance of very early treatment. Arch Neurol. 1999;56:1104-1108.
31. Albers GW, Bittar N, Young L, Hattemer CR, Gandhi AJ, Kemp SM, Hall EA, Morton DJ, Yim J, Vlasses PH. Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals. Neurology. 1997;48:1598-1604.
32. Chamorro A. Immediate anticoagulation in acute focal brain ischemia revisited: Gathering the evidence. Stroke. 2001;32:577-578.
33. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after TIA or minor stroke. Lancet. 1993;342:255-262.
34. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8:141-151.
35. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.